Skip to main content
Premium Trial:

Request an Annual Quote

Assurex Pharmacogenomics Tests to Use Luminex xTag Technology

NEW YORK (GenomeWeb) – Luminex today announced that its xTAG universal tag technology has been selected for use in Assurex Health's GeneSight neuropsychiatric pharmacogenomics tests.

Gene Sight compares patients' DNA signatures with known pharmacology in order to predict how they might react to medicines used to treat depression, post-traumatic stress disorder, anxiety, bipolar disease, schizophrenia, and other behavioral health conditions.

According to Luminex, its technology will enhance the processing speed and capacity of the Gene Sight tests. "In addition, the flexibility of the Luminex platform will allow us to add new biomarkers as our needs continue to expand," Assurex COO Donald Wright said in a statement.

Specific terms of the arrangement were not disclosed.

The Scan

Steps for Quick Review

The US Food and Drug Administration is preparing for the quick review of drugs and vaccines for the Omicron variant, according to the Wall Street Journal.

Moving Away From Using Term 'Race'

A new analysis finds that geneticists are using the term "race" in their papers less than in years past, as Science reports.

Point of the Program

The Guardian writes that some scientists have called the design of a UK newborn sequencing program into question.

Science Papers Present Multi-Omic Analysis of Lung Cells, Regulation of Cardiomyocyte Proliferation

In Science this week: a multi-omic analysis of lung cells focuses on RIT1-regulated pathways, and more.